Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
Anna F. Farago(Massachusetts General Hospital), Benjamin J. Drapkin(Southwestern Medical Center), Judith Marcoux(Beth Israel Deaconess Medical Center), Taronish D. Dubash(Harvard University), Daniel A. Haber(Howard Hughes Medical Institute), Yin P. Hung(Harvard University), Deepa Rangachari(Massachusetts General Hospital), Subba R. Digumarthy(Massachusetts General Hospital), Nicholas J. Dyson(Massachusetts General Hospital), David A. Barbie(Dana-Farber Cancer Institute), Rebecca S. Heist(Massachusetts General Hospital), Marina Kem(Massachusetts General Hospital), Marcello Stanzione(Massachusetts General Hospital), Shyamala Maheswaran(Massachusetts General Hospital), Michael S. Lawrence(Broad Institute), Mari Mino–Kenudson(Massachusetts General Hospital), Lecia V. Sequist(Harvard University), Alice T. Shaw(Dana-Farber Cancer Institute), Jun Zhong(Massachusetts General Hospital), Elizabeth A. Kennedy(University of Pennsylvania), Aaron N. Hata(Harvard University), David T. Myers(Harvard University), Sarah Phat(Harvard University), Beow Y. Yeap(Harvard University), Robert Morris(Massachusetts General Hospital)
Cited by 238
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k